Mucosal Drug Penetration Across the Upper Airway Epithelium: Mechanisms, Clinical Relevance, and Emerging Evidence

Abstract

Mucosal drug penetration across the upper airway epithelium is a critical determinant of pharmacologic efficacy in the management of various respiratory and otolaryngological disorders. This review synthesizes current evidence on the mechanisms, influencing factors, and clinical implications of drug delivery through the nasal and pharyngeal mucosa, with an emphasis on recent advances and guideline-based recommendations. Enhanced understanding of epithelial barriers, drug transport pathways, and formulation strategies is essential for optimizing therapeutic outcomes and guiding future innovation in topical and systemic drug delivery for upper airway diseases.

Introduction

The upper airway epithelium, encompassing the nasal cavity, nasopharynx, and oropharynx, serves as both a protective barrier and a potential route for drug administration. Efficient mucosal drug penetration is fundamental to the success of topical therapies for allergic rhinitis, chronic rhinosinusitis, and infectious diseases, as well as for systemic delivery via the intranasal route. Recent advances in epithelial biology, drug formulation, and delivery technologies have expanded therapeutic options, yet variability in mucosal absorption and the complexity of the epithelial barrier continue to pose significant clinical challenges. This article reviews the scientific basis, clinical implications, and evolving landscape of mucosal drug penetration across the upper airway epithelium, with practical insights for healthcare professionals aiming to optimize patient outcomes.

Epidemiology / Disease Burden

Respiratory and upper airway conditions, including allergic rhinitis, chronic rhinosinusitis, and viral infections, affect a substantial proportion of the global population. The World Health Organization estimates that up to 20-30% of adults suffer from allergic rhinitis, while chronic rhinosinusitis impacts nearly 11% of individuals worldwide. These disorders impose significant healthcare costs, reduce quality of life, and contribute to lost productivity. The high prevalence underscores the necessity for effective, minimally invasive therapeutic strategies, making mucosal drug delivery an area of intense clinical and research focus.

Pathophysiology

The upper airway epithelium is composed of pseudostratified ciliated columnar cells, tight junctions, goblet cells, and subepithelial immune structures. Its primary physiological role is to protect underlying tissues from pathogens, allergens, and particulates. The epithelial barrier is maintained by intercellular junctional complexes primarily tight junctions containing claudins and occludins that regulate paracellular permeability. Inflammatory states, such as those seen in allergic rhinitis or chronic infection, can disrupt these barriers, altering permeability and influencing drug absorption. Additionally, mucociliary clearance and enzymatic activity can impact the residence time and stability of administered agents.

Risk Factors

Several factors modulate the efficiency of mucosal drug penetration across the upper airway epithelium. Intrinsic patient variables include age, epithelial integrity, genetic polymorphisms affecting transporter expression, and comorbid conditions such as diabetes or chronic inflammation. Extrinsic factors encompass the physicochemical properties of the drug (molecular weight, lipophilicity, charge), formulation type (solutions, suspensions, gels), and delivery method (sprays, nebulizers, drops). Procedures or disease states that alter mucosal integrity, such as previous surgery, radiation, or acute infections, can further influence drug uptake and therapeutic response.

Clinical Features

Clinically, the consequences of variable mucosal drug penetration manifest as suboptimal therapeutic effects, local irritation, or systemic side effects. For example, inadequate penetration of topical corticosteroids in allergic rhinitis may result in persistent symptoms, while excessive absorption may increase systemic corticosteroid exposure. Nasal drug delivery for migraine or seizure management relies on rapid and consistent mucosal penetration for timely therapeutic action. Understanding the interplay between drug properties, mucosal health, and delivery technique is therefore crucial in tailoring interventions for individual patients.

Diagnosis

Assessment of mucosal drug penetration is primarily indirect, relying on clinical response, symptom tracking, and, in research settings, pharmacokinetic studies measuring drug concentrations in local tissues or systemic circulation. Advanced imaging techniques, such as single-photon emission computed tomography (SPECT) and positron emission tomography (PET), have been utilized to evaluate regional drug distribution following intranasal administration. Non-invasive biomarkers of epithelial integrity, including nasal nitric oxide levels and cytology, may provide adjunctive information in select contexts.

Treatment & Management

Optimizing mucosal drug penetration involves selection of appropriate drug formulations, delivery devices, and application techniques. Strategies include use of mucoadhesive agents to prolong mucosal contact, permeation enhancers to transiently loosen tight junctions, and nanoparticles or liposomes to facilitate intracellular transport. In clinical practice, patient education regarding head position, spray angle, and device priming is vital. For patients with disrupted mucosa or high mucociliary clearance, alternative routes or systemic therapies may be warranted. Monitoring for local side effects, such as epistaxis or mucosal dryness, is essential to ensure safety and adherence.

Recent Advances / Emerging Therapies

Recent research has focused on engineered nanoparticles, peptide-based permeation enhancers, and bioresponsive hydrogels to enhance mucosal drug delivery across the upper airway. Studies have demonstrated that chitosan-based nanoparticles can improve the nasal absorption of peptides and proteins, while cell-penetrating peptides show promise in facilitating the transport of large molecules across the epithelial barrier. Microarray patches and novel delivery devices are being explored for precise, targeted deposition of drugs onto the nasal mucosa. Advances in personalized medicine, including genotyping for transporter polymorphisms, may soon allow for individualized drug delivery strategies based on mucosal absorption profiles.

Guideline Recommendations

Evidence-based guidelines from organizations such as the American Academy of Otolaryngology and the European Academy of Allergy and Clinical Immunology emphasize the importance of proper delivery techniques and patient education in optimizing topical therapy for upper airway diseases. Selection of formulations with proven mucosal penetration, avoidance of unnecessary systemic exposure, and regular assessment of response are recommended. For intranasal corticosteroids, guidelines advocate for continuous, rather than intermittent, use and highlight the low systemic bioavailability when used correctly. Emerging therapies should be evaluated in the context of robust clinical trials before routine adoption.

Conclusion

Mucosal drug penetration across the upper airway epithelium is a multifaceted process influenced by epithelial biology, drug and formulation characteristics, and patient-specific factors. Advances in drug delivery science offer promising avenues for improving therapeutic efficacy and patient outcomes in upper airway diseases. Continued research, adherence to clinical guidelines, and individualized patient management are essential to overcome current limitations and harness the full potential of mucosal drug delivery in respiratory and otolaryngologic practice.